Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Show simple item record

dc.contributor University of Helsinki, HUS Comprehensive Cancer Center en
dc.contributor.author Lauseker, Michael
dc.contributor.author Bachl, Katharina
dc.contributor.author Turkina, Anna
dc.contributor.author Faber, Edgar
dc.contributor.author Prejzner, Witold
dc.contributor.author Olsson-Stromberg, Ulla
dc.contributor.author Baccarani, Michele
dc.contributor.author Lomaia, Elza
dc.contributor.author Zackova, Daniela
dc.contributor.author Ossenkoppele, Gert
dc.contributor.author Griskevicius, Laimonas
dc.contributor.author Schubert-Fritschle, Gabriele
dc.contributor.author Sacha, Tomasz
dc.contributor.author Heibl, Sonja
dc.contributor.author Koskenvesa, Perttu
dc.contributor.author Bogdanovic, Andrija
dc.contributor.author Clark, Richard E.
dc.contributor.author Guilhot, Joelle
dc.contributor.author Hoffmann, Verena S.
dc.contributor.author Hasford, Joerg
dc.contributor.author Hochhaus, Andreas
dc.contributor.author Pfirrmann, Markus
dc.date.accessioned 2019-11-08T10:53:01Z
dc.date.available 2019-11-08T10:53:01Z
dc.date.issued 2019-11
dc.identifier.citation Lauseker , M , Bachl , K , Turkina , A , Faber , E , Prejzner , W , Olsson-Stromberg , U , Baccarani , M , Lomaia , E , Zackova , D , Ossenkoppele , G , Griskevicius , L , Schubert-Fritschle , G , Sacha , T , Heibl , S , Koskenvesa , P , Bogdanovic , A , Clark , R E , Guilhot , J , Hoffmann , V S , Hasford , J , Hochhaus , A & Pfirrmann , M 2019 , ' Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin ' , American Journal of Hematology , vol. 94 , no. 11 , pp. 1236-1243 . https://doi.org/10.1002/ajh.25628 en
dc.identifier.issn 0361-8609
dc.identifier.other PURE: 127990937
dc.identifier.other PURE UUID: 4d95f5e9-09c7-4ef7-9b6f-2901d5055a68
dc.identifier.other WOS: 000490182700018
dc.identifier.uri http://hdl.handle.net/10138/306832
dc.description.abstract Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known about the prognosis of these patients. Our aim was to identify prognostic factors for this cohort. We identified 283 patients in the EUTOS population-based and out-study registries that were diagnosed in advanced phase. Nearly all patients were treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was 8.2 years. When comparing patients with more than 30% blasts to those with 20-29% blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts (HR: 2.24, 95%-CI: [1.2-4.0], P = .008). We found that the blast count was the most important prognostic factor; however, age, hemoglobin, basophils and other chromosomal aberrations should be considered as well. The ELTS score was able to define two groups (high risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P <.001). Regarding the contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the 30% cut-off in this cohort. Based on our results, we conclude that a one-phase rather than a two-phase categorization of de novo advanced phase CML patients is appropriate. en
dc.format.extent 8
dc.language.iso eng
dc.relation.ispartof American Journal of Hematology
dc.rights en
dc.subject WORLD-HEALTH-ORGANIZATION en
dc.subject CHRONIC MYELOGENOUS LEUKEMIA en
dc.subject TYROSINE KINASE INHIBITORS en
dc.subject 2904 CML PATIENTS en
dc.subject RANDOMIZED CML en
dc.subject SURVIVAL en
dc.subject MANAGEMENT en
dc.subject IMATINIB en
dc.subject ERA en
dc.subject RECOMMENDATIONS en
dc.subject 3122 Cancers en
dc.title Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin en
dc.type Article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.1002/ajh.25628
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/publishedVersion
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
Lauseker_et_al_ ... _Journal_of_Hematology.pdf 1.373Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record